Latest News

31-03-2015 Cancer Pilot Study Success
31-03-2015 Joint Company Secretary Appointment
27-02-2015 Half Year Statement
24-02-2015 Europe Patent Phenotypic Screening
17-02-2015 Shareholder Update February 2015
News archive

Subscribe to our newsletter

Receive our latest news and announcements instantly


Phylogica is a leading peptide drug discovery company that utilises proprietary Phylomer peptide libraries and screening methodologies to identify unique peptide drug candidates for its pharmaceutical and biotechnology partners.

Phylomer® libraries contain the world's largest and most structurally diverse array of natural peptides. These peptides, known as Phylome® peptides, are sourced from evolutionary diverse microbes and they represent a new class of biological therapeutics. Phylomer® peptides display exceptional structural stability, specificity and affinity thereby giving them the potential to address disease targets that are intractable to small molecules and other protein biologics including antibodies. Read more



© 2015 Phylogica    |    ABN 48 098 391 961    |    Privacy Statement
Last updated: 31-03-2015    |    Website by Harmonic New Media and College Hill Life Sciences